The combined application of drugs that block TIGIT and PD-1 (Atezolizumab/Tiragolumab) can upregulate CD8+ T cell expression and function, which may be considered as a potential cancer immunotherapy strategy (144). This evidence concerns the gene TIGIT and cancer.